NYSE · APUS
Apimeds Pharmaceuticals US, Inc.
Latest quarter · ended Jun 30, 2026
Cash got weaker
Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.
Smart money pulse
What insiders and funds are doing
- infoNo real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.
−100 means everyone selling, +100 everyone buying. This is data, not advice.
How the Pulse works
Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.
Who owns it
7 funds report owning APUS, up from 6
Insider trades · last 12 months
Real buys and sales
No insider filings loaded for the last 12 months.
Top holders
Biggest funds in APUS
| Fund | Owns | Value | Change |
|---|---|---|---|
| Hemenway Trust Co LLC | 18.2% | $247K | Same |
| Vanguard Capital Management LLC | 4.2% | $57.3K | −34% |
| Geode Capital Management, LLC | 2.3% | $31.6K | −12% |
| Vanguard Fiduciary Trust Co | 1.6% | $21.6K | Same |
| Jane Street Group, LLC | 1.1% | $14.4K | New |
"Owns" is shares reported divided by shares outstanding.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.